Robert W Mcdowell

US Patent:

7094869, Aug 22, 2006

Filed:

Aug 19, 2002

Appl. No.:

10/224640

Inventors:

Todd C. Somers - Foster City CA, US
Kathleen A. Elias - San Francisco CA, US
Ross G. Clark - Pacifica CA, US
Robert S. McDowell - San Francisco CA, US
Mark S. Stanley - Pacifica CA, US
John P. Burnier - Pacifica CA, US
Thomas E. Rawson - Mountain View CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07K 5/08

US Classification:

530331, 530330, 517 17, 517 18

Abstract:

The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.

US Patent:

20020111461, Aug 15, 2002

Filed:

May 21, 1999

Appl. No.:

09/316505

Inventors:

TODD C. SOMERS - FOSTER CITY CA, US
KATHLEEN A. ELIAS - SAN FRANCISCO CA, US
ROSS G. CLARK - PACIFICA CA, US
ROBERT S. MCDOWELL - SAN FRANCISCO CA, US
MARK S. STANLEY - PACIFICA CA, US
JOHN P. BURNIER - PACIFICA CA, US
THOMAS E. RAWSON - MOUNTAIN VIEW CA, US

International Classification:

A61K038/00
C07K005/00
C07K007/00
C07K016/00
C07K017/00
A61K038/04
A61K038/06

US Classification:

530/330000, 530/331000, 514/017000, 514/018000

Abstract:

The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.

US Patent:

20050203135, Sep 15, 2005

Filed:

Aug 26, 2003

Appl. No.:

10/649762

Inventors:

Daniel Burdick - Burlingame CA, US
Thomas Gadek - Oakland CA, US
Robert McDowell - San Francisco CA, US
James Marsters - Oakland CA, US
David Oare - Belmont CA, US
Mark Reynolds - Millbrae CA, US
Mark Stanley - Pacifica CA, US
Kenneth Weese - South San Francisco CA, US

International Classification:

C07D211/56
C07D213/75
A61K031/445
A61K031/44
A61K031/195

US Classification:

514317000, 514352000, 514426000, 514447000, 514471000, 514563000, 546223000, 546309000, 548557000, 549065000, 549480000, 562450000

Abstract:

Compounds of the general structure D-L-B-(AA), for example (A), that are useful for treating Mac-1 or LFA-1-mediated disorders such as inflammatory disorders, allergies, and autoimmune diseases are provided.

US Patent:

20060063807, Mar 23, 2006

Filed:

May 25, 2005

Appl. No.:

11/138705

Inventors:

Todd Somers - Foster City CA, US
Kathleen Elias - San Francisco CA, US
Ross Clark - Pacifica CA, US
Robert McDowell - San Francisco CA, US
Mark Stanley - Pacifica CA, US
John Burnier - Pacifica CA, US
Thomas Rawson - Mountain View CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 31/4545
A61K 31/454
C07D 401/02
C07D 403/14

US Classification:

514316000, 514317000, 546187000, 546190000, 546201000

Abstract:

The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.

US Patent:

20100015093, Jan 21, 2010

Filed:

Mar 18, 2009

Appl. No.:

12/383071

Inventors:

Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US

International Classification:

A61K 38/21
A61K 31/416
C12N 5/00
C07D 231/56
C07D 401/12
A61K 31/454
A61P 31/12
C07D 403/12

US Classification:

424 857, 514403, 435377, 424 854, 5483611, 546199, 514322

Abstract:

Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.

US Patent:

20100028299, Feb 4, 2010

Filed:

Mar 18, 2009

Appl. No.:

12/383030

Inventors:

Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US

International Classification:

A61K 38/21
A61K 31/4184
C07D 403/02
C07D 403/12
C07D 471/04
A61K 31/497
A61K 31/4439
A61K 31/708
A61P 31/12

US Classification:

424 857, 514394, 5483061, 544370, 546118, 51425406, 514303, 514 43

Abstract:

Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.

US Patent:

20100125036, May 20, 2010

Filed:

Sep 19, 2006

Appl. No.:

11/533220

Inventors:

Ramesh K. Sharma - Sunnyvale CA, US
Kyle L. Fujdala - San Jose CA, US
Timothy J. Truex - Oxnard CA, US
Robert McDowell - Sheridan WY, US
Jifei Jia - Mountain View CA, US

International Classification:

B01J 23/42
B01J 23/44
B01J 23/52
B01J 21/04

US Classification:

502330, 502333

Abstract:

A method for preparing a catalyst that involves continuously supplying a first stream containing a solvent, one or more metal precursors, and one or more support materials, and a second stream containing at least one reducing agent and/or precipitating agent. The first and second streams are combined to form a combined stream. In one embodiment, the combined stream may be fed to a mixing vessel. In another embodiment, the streams are combined in a mixing vessel. After the streams are combined, one or more metal precursors is reduced or precipitated within the pores of the one or more support materials. Thereafter, solids are separated from the combined stream and processed to produce the supported metal, mixed-metal, metal oxide, or mixed-metal oxide catalyst. In another embodiment, ceramic or metallic monoliths may be coated with the catalytic material after the stream combination and before or after the solid separation and subsequent processing.

US Patent:

20100260717, Oct 14, 2010

Filed:

Sep 18, 2008

Appl. No.:

12/678014

Inventors:

Stephen R. Quake - Stanford CA, US
Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
Wenjin Yang - Forster City CA, US
Doron Gerber - Mountain View CA, US

International Classification:

A61K 38/21
A61K 31/4184
A61K 31/137
A61K 31/4025
A61K 31/4406
A61K 31/17
G01N 33/566
A61P 31/14

US Classification:

424 857, 514394, 514653, 514409, 514357, 514597, 436501

Abstract:

Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of identifying a candidate agent for the treatment of hepatitis C virus (HCV) infection, and the like.